Basic information Safety Related Supplier

ChemicalBook Product Catalog IT-901

1/1

IT-901 NEW

$122.00 5mg

$197.00 10mg

$413.00 25mg

Min. Order
Purity98.06%
Cas No1584121-99-2
Supply Ability10g
Update time2024-11-06

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

5YR

United States

show more

Chemical Properties

Product Name	IT-901
CAS No	1584121-99-2
EC-No
Min. Order
Purity	98.06%
Supply Ability	10g
Release date	2024/11/06

Product Introduction

Bioactivity

名称	IT-901
描述	IT-901 is an orally active and potent NF-κB subunit c-Rel inhibitor with IC50 values for NF-κB and c-Rel binding to DNA of 0.1 µM and 3 µM, respectively. IT-901 is a naphthalene thiobarbiturate derivative with antitumor activity and is used for the prevention and treatment of human lymphoma and myeloma.
体外活性	Following 24 hours of treatment with IT-901 at concentrations of 1, 3, and 5 μM, there is a reduction in the proliferation of viable ABC and GCB DLBCL cells[2]. At a concentration of 3 μM and a duration of 24 hours, IT-901 induces a dose-dependent decrease in cell viability. However, at least 60 percent of cells remain viable after 48 hours of treatment with 4 μM IT-901 in all tested cell lines, except HBL1[2]. With a treatment duration of 6 hours and concentrations of 1, 5, and 10 μM, IT-901 leads to a diminished expression of p65 and p50 in both nuclear and cytosolic fractions. Additionally, it reduces the expression of the inhibitory subunit IκBα in both phosphorylated and non-phosphorylated forms in primary CLL cells and cell lines[2].The IC50 of IT-901/GDM-12 is 2.9 μM for c-Rel, while IL-2 secretion is effectively blocked at 5 μM[2]. Concentrations of IT-901 above 10 μM become increasingly toxic and may induce apoptosis in healthy cells[2]. IT-901 demonstrates inhibition of cell growth in both activated B-like (ABC) and germinal center B-like (GCB) cell lines, with IC50 values ranging between 3 μM to 4 μM[2].
体内活性	Administered intraperitoneally (IP) every other day for 2 weeks at a dose of 24 mg/kg, IT-901 proves to be an effective treatment for acute graft-versus-host disease (GVHD) without compromising its anti-tumor activity[2]. IT-901, given at doses ranging from 12 to 20 mg/kg via IP administration, enhances the pharmacokinetic (PK) profile by increasing both half-life (T1/2) and maximum plasma concentration (Cmax)[2].
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 10 mg/mL (29.21 mM), Sonication is recommended.
关键字	IT901 \| IT-901 \| IT 901
相关库	经典已知活性库 \| 抑制剂库 \| 已知活性化合物库

show more

Company Profile Introduction

You may like

Recommended supplier

MSDS|CAS|CAS DataBase|Pricacy|Terms|About Us|New Products| Contact us|Computer Version
Chemical Book